Contributors |
|
xi | |
Acknowledgments |
|
xiii | |
Periodic table of the elements |
|
xv | |
Introduction |
|
xvii | |
|
|
|
1 Clinical and immunological effects and biomarkers of zinc deficiency |
|
|
|
|
|
3 | (1) |
|
2 Discovery of zinc deficiency in human |
|
|
4 | (3) |
|
|
4 | (1) |
|
|
5 | (1) |
|
2.3 Chronology of other important observations in human zinc deficiency |
|
|
6 | (1) |
|
3 Clinical effects of zinc deficiency |
|
|
7 | (3) |
|
|
7 | (1) |
|
|
8 | (1) |
|
|
8 | (2) |
|
4 Biochemical and immunological effects of zinc |
|
|
10 | (7) |
|
|
10 | (1) |
|
|
10 | (2) |
|
|
12 | (3) |
|
4.4 Zinc and cell membrane |
|
|
15 | (1) |
|
|
16 | (1) |
|
4.6 Zinc and gene expression |
|
|
16 | (1) |
|
4.7 Interactions of zinc with other elements |
|
|
17 | (1) |
|
4.8 Zinc and free radicals |
|
|
17 | (1) |
|
5 Biomarkers of zinc deficiency |
|
|
17 | (4) |
|
|
17 | (1) |
|
5.2 Atomic absorption spectrophotometry for assaying zinc in biological samples |
|
|
18 | (1) |
|
5.3 Development of biomarkers of zinc deficiency in experimental human zinc deficiency model |
|
|
18 | (1) |
|
5.4 Zinc in plasma and blood cells |
|
|
18 | (1) |
|
5.5 Changes in zinc-dependent enzymes |
|
|
18 | (1) |
|
5.6 Serum thymulin activity as a biomarker of human zinc deficiency |
|
|
19 | (1) |
|
5.7 Development of immunological biomarkers of human zinc deficiency |
|
|
19 | (1) |
|
5.8 Endogenous excretion of zinc as a biomarker of zinc deficiency |
|
|
20 | (1) |
|
6 Clinical impact of zinc |
|
|
21 | (10) |
|
|
21 | (2) |
|
|
23 | (1) |
|
6.3 Renal disease and zinc |
|
|
24 | (1) |
|
6.4 Age-related macular degeneration (AMD) and zinc |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
26 | (4) |
|
|
30 | (1) |
|
2 Zinc and the immune system: Insights into the role of zinc in autoimmune diseases |
|
|
|
|
|
|
31 | (1) |
|
|
31 | (1) |
|
|
32 | (1) |
|
4 Effect of zinc on the immune system |
|
|
32 | (16) |
|
|
33 | (8) |
|
|
41 | (7) |
|
|
48 | (7) |
|
|
48 | (7) |
|
3 Zinc transporters in physiology and pathophysiology |
|
|
|
|
|
|
|
|
|
1 Zinc as an essential mineral for life |
|
|
55 | (1) |
|
1.1 Zinc signaling and zinc stress |
|
|
55 | (1) |
|
1.2 Zinc level in organelles |
|
|
56 | (1) |
|
2 Zinc homeostasis by zinc transporters and their biological relevance |
|
|
56 | (4) |
|
2.1 Physiology and pathophysiology of ZnT family members |
|
|
56 | (1) |
|
2.2 ZIP physiology and pathophysiology |
|
|
57 | (3) |
|
3 Recent advances of investigation of zinc transporters and skin disorders |
|
|
60 | (1) |
|
|
60 | (1) |
|
|
61 | (1) |
|
4 Conclusions and perspectives |
|
|
61 | (8) |
|
|
62 | (7) |
|
|
|
|
|
69 | (1) |
|
|
69 | (4) |
|
|
69 | (1) |
|
2.2 Clinical presentation, recognition, and diagnosis |
|
|
70 | (1) |
|
|
71 | (2) |
|
3 Menkes disease and ATP7A-related copper transport diseases |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (1) |
|
5 Occipital horn syndrome |
|
|
74 | (1) |
|
6 ATP7A-related distal motor neuropathy |
|
|
74 | (1) |
|
7 Copper toxicity in Alzheimer's disease |
|
|
74 | (3) |
|
8 The potential benefits of "copper lowering therapy" in a variety of diseases |
|
|
77 | (1) |
|
|
77 | (1) |
|
8.2 Fibrotic, inflammatory, and autoimmune diseases |
|
|
77 | (1) |
|
9 Clinical copper deficiency |
|
|
78 | (5) |
|
|
79 | (4) |
|
|
|
|
|
1 Biochemical properties of iron |
|
|
83 | (1) |
|
|
83 | (6) |
|
2.1 Dietary iron absorption |
|
|
84 | (1) |
|
2.2 Iron in the circulation |
|
|
85 | (1) |
|
2.3 Uptake of iron by erythroid cells and synthesis of heme |
|
|
86 | (1) |
|
2.4 Iron processing by macrophages |
|
|
86 | (1) |
|
|
87 | (1) |
|
2.6 Systemic regulation of iron homeostasis by hepcidin |
|
|
87 | (2) |
|
3 Imbalances in iron homeostasis |
|
|
89 | (6) |
|
|
89 | (1) |
|
3.2 Increased iron stores and iron overload |
|
|
90 | (5) |
|
|
95 | (8) |
|
|
95 | (8) |
|
|
|
|
|
|
103 | (1) |
|
2 Epidemiology of iodine deficiency |
|
|
103 | (1) |
|
3 Assessment of iodine status |
|
|
104 | (2) |
|
3.1 Urinary iodine concentration |
|
|
104 | (1) |
|
|
105 | (1) |
|
3.3 Thyroid stimulating hormone and thyroid hormones |
|
|
105 | (1) |
|
|
105 | (1) |
|
|
106 | (1) |
|
4 Consequences of residing in iodine-deficient regions |
|
|
106 | (1) |
|
5 Consequences of mild to moderate iodine deficiency |
|
|
106 | (1) |
|
|
107 | (1) |
|
6.1 Delivering effective iodine supplementation |
|
|
107 | (1) |
|
|
107 | (1) |
|
8 Iodine metabolism and its role in metabolism |
|
|
108 | (2) |
|
|
108 | (1) |
|
|
108 | (1) |
|
8.3 Iodine and auto-immunity |
|
|
109 | (1) |
|
8.4 Iodine and its role in epigenetics |
|
|
109 | (1) |
|
|
110 | (1) |
|
|
110 | (3) |
|
|
|
|
|
|
113 | (1) |
|
2 Dietary selenium intake |
|
|
114 | (1) |
|
|
114 | (1) |
|
|
114 | (1) |
|
2.3 Dietary recommendations |
|
|
115 | (1) |
|
|
115 | (2) |
|
|
116 | (1) |
|
|
116 | (1) |
|
3.3 Urinary selenium excretion |
|
|
116 | (1) |
|
3.4 Nail and hair selenium concentrations |
|
|
117 | (1) |
|
3.5 Determinants of selenium biomarkers |
|
|
117 | (1) |
|
4 Selenoproteins, biological functions, and potential health effects |
|
|
117 | (1) |
|
|
117 | (5) |
|
|
117 | (3) |
|
|
120 | (1) |
|
5.3 Cardiovascular disease |
|
|
120 | (1) |
|
5.4 Stroke and other neurological diseases |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
122 | (1) |
|
|
122 | (5) |
|
|
122 | (5) |
|
8 Unifying mechanisms of trivalent chromium in health and disease |
|
|
|
|
|
|
127 | (1) |
|
2 Clinical benefits of chromium supplementation |
|
|
127 | (1) |
|
3 New mechanistic aspects of chromium action |
|
|
128 | (5) |
|
|
129 | (1) |
|
|
130 | (1) |
|
3.3 Inflammatory response and vascular function |
|
|
131 | (1) |
|
|
132 | (1) |
|
|
133 | (8) |
|
|
134 | (7) |
|
|
|
|
|
|
|
141 | (1) |
|
|
141 | (4) |
|
|
142 | (1) |
|
|
142 | (2) |
|
|
144 | (1) |
|
|
145 | (1) |
|
|
145 | (3) |
|
3.1 Sources and routes of exposure |
|
|
145 | (1) |
|
|
146 | (1) |
|
3.3 Mitochondrial dysfunction |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
148 | (1) |
|
|
148 | (5) |
|
|
148 | (1) |
|
|
148 | (5) |
|
10 Fluorine in human metabolism, health and disease |
|
|
|
|
|
|
|
|
|
153 | (1) |
|
2 Routes of fluoride exposure |
|
|
154 | (1) |
|
|
154 | (1) |
|
|
154 | (1) |
|
|
154 | (1) |
|
|
155 | (1) |
|
|
155 | (1) |
|
8 Fluorine in human health and disease |
|
|
155 | (3) |
|
|
155 | (2) |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
158 | (1) |
|
9 Endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) |
|
|
158 | (1) |
|
|
159 | (6) |
|
|
160 | (5) |
|
Part II Toxic trace elements |
|
|
|
11 Arsenic skin carcinogenesis: A prototypic model of chemical carcinogenesis featured with abnormal differentiation and aberrant immune responses |
|
|
|
|
|
|
|
165 | (1) |
|
2 The plausible mechanism of arsenic carcinogenesis |
|
|
166 | (1) |
|
3 Mechanisms of arsenic-induced skin cancer |
|
|
166 | (1) |
|
4 Abnormal epidermal differentiation in arsenical cancers |
|
|
167 | (1) |
|
5 Abnormal proliferation and apoptosis in arsenical cancers |
|
|
168 | (1) |
|
6 Aberrant immune responses by arsenic |
|
|
168 | (3) |
|
|
169 | (2) |
|
12 Emerging importance of manganese and arsenic as modifiers of cadmium accumulation |
|
|
|
|
|
|
171 | (1) |
|
2 Cd accumulation in the kidney among rice-eating human populations |
|
|
172 | (1) |
|
3 Transport of Cd and Mn via Zn transporters in mammals |
|
|
173 | (2) |
|
4 Cd uptake via Mn transporter in rice |
|
|
175 | (1) |
|
5 Trade-off relationship of Cd and As accumulation in rice |
|
|
175 | (2) |
|
|
177 | (4) |
|
|
177 | (4) |
|
|
|
|
|
181 | (3) |
|
|
182 | (1) |
|
|
182 | (1) |
|
|
182 | (1) |
|
1.4 Intake and metabolism |
|
|
183 | (1) |
|
|
184 | (3) |
|
2.1 Hematopoietic effects |
|
|
185 | (1) |
|
2.2 Effect on the cardiovascular system |
|
|
185 | (1) |
|
2.3 Effect on the neurological system |
|
|
186 | (1) |
|
2.4 Effect on the renal system |
|
|
186 | (1) |
|
2.5 Effect on other organ systems |
|
|
187 | (1) |
|
3 Treatment of Lead poisoning in humans |
|
|
187 | (6) |
|
|
188 | (3) |
|
|
191 | (2) |
|
14 Methylmercury: Human exposure, animal behavior, and insight on molecular mechanism |
|
|
|
|
|
|
|
193 | (1) |
|
|
194 | (1) |
|
|
194 | (2) |
|
|
195 | (1) |
|
|
195 | (1) |
|
|
196 | (1) |
|
5 Mechanism(s) of toxicity |
|
|
197 | (1) |
|
|
197 | (6) |
|
|
198 | (1) |
|
|
198 | (2) |
|
|
200 | (3) |
|
|
|
|
|
|
|
|
|
|
203 | (3) |
|
2 Metabolism and regulation |
|
|
206 | (3) |
|
2.1 Digestion and absorption |
|
|
206 | (1) |
|
|
207 | (1) |
|
2.3 Hepatic uptake, storage, and secretion |
|
|
207 | (1) |
|
2.4 Recycling/conservation (recycling and renal reuptake) |
|
|
208 | (1) |
|
2.5 Oxidative metabolism and excretion |
|
|
208 | (1) |
|
2.6 Nuclear activity of retinoic acid |
|
|
209 | (1) |
|
|
209 | (2) |
|
|
209 | (1) |
|
|
210 | (1) |
|
3.3 Assessment of vitamin A status |
|
|
210 | (1) |
|
4 Vitamin A in the life cycle |
|
|
211 | (1) |
|
4.1 Vitamin A status at birth |
|
|
211 | (1) |
|
5 Current nutritional recommendations |
|
|
212 | (5) |
|
|
212 | (5) |
|
|
|
|
|
217 | (2) |
|
|
218 | (1) |
|
|
218 | (1) |
|
|
218 | (1) |
|
|
218 | (1) |
|
1.5 Miscellaneous aspects |
|
|
219 | (1) |
|
|
219 | (1) |
|
2 Vitamin B2 (riboflavin) |
|
|
219 | (2) |
|
|
219 | (1) |
|
|
219 | (1) |
|
|
220 | (1) |
|
|
220 | (1) |
|
2.5 Miscellaneous aspects |
|
|
220 | (1) |
|
|
220 | (1) |
|
|
221 | (1) |
|
|
221 | (1) |
|
|
221 | (1) |
|
|
222 | (1) |
|
|
222 | (1) |
|
3.5 Miscellaneous aspects |
|
|
222 | (1) |
|
|
222 | (1) |
|
|
222 | (2) |
|
|
223 | (1) |
|
|
223 | (1) |
|
|
223 | (1) |
|
|
223 | (1) |
|
|
224 | (1) |
|
|
224 | (1) |
|
|
224 | (3) |
|
|
224 | (1) |
|
|
225 | (1) |
|
|
225 | (1) |
|
|
226 | (1) |
|
|
226 | (1) |
|
|
226 | (1) |
|
|
227 | (2) |
|
|
227 | (1) |
|
|
227 | (1) |
|
|
227 | (1) |
|
|
228 | (1) |
|
|
228 | (1) |
|
|
228 | (1) |
|
|
229 | (1) |
|
|
229 | (1) |
|
|
229 | (1) |
|
|
229 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
230 | (12) |
|
|
230 | (1) |
|
|
231 | (1) |
|
|
231 | (1) |
|
|
231 | (1) |
|
|
231 | (1) |
|
|
231 | (1) |
|
|
231 | (11) |
|
|
|
|
|
|
1 Chemistry and biochemistry |
|
|
242 | (4) |
|
1.1 Ascorbic acid chemistry, measurement, and catabolism |
|
|
242 | (1) |
|
1.2 Chemistry: Synthesis in animals---In vivo |
|
|
243 | (1) |
|
1.3 Chemistry: Synthesis in vitro |
|
|
243 | (1) |
|
1.4 Ascorbic acid: Chemical reductant in vivo and in vitro |
|
|
244 | (1) |
|
1.5 Ascorbic acid biochemistry: Reduction reactions: Enzymology |
|
|
245 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
2.3 Transmembrane electron transfer |
|
|
246 | (1) |
|
3 Physiology and pharmacokinetics of vitamin C in humans: Tight control of vitamin C concentrations |
|
|
246 | (5) |
|
|
246 | (1) |
|
3.2 Physiology and pharmacokinetics: Plasma concentrations and tight control |
|
|
247 | (1) |
|
|
247 | (2) |
|
|
249 | (1) |
|
3.5 Renal reabsorption and excretion |
|
|
249 | (1) |
|
|
250 | (1) |
|
3.7 Physiology and pharmacokinetics studies of vitamin C: Limitations |
|
|
250 | (1) |
|
4 Pharmacology and pathophysiology |
|
|
251 | (3) |
|
|
251 | (1) |
|
|
251 | (2) |
|
4.3 Sepsis and acute respiratory distress syndrome |
|
|
253 | (1) |
|
4.4 Diabetes, dehydroascorbic acid, and red blood cells |
|
|
253 | (1) |
|
5 Vitamin C consumption in humans |
|
|
254 | (2) |
|
5.1 Dietary sources of vitamin C |
|
|
254 | (1) |
|
5.2 Dietary Reference Intakes and use categories |
|
|
255 | (1) |
|
5.3 Special considerations for Dietary Reference Intakes |
|
|
255 | (1) |
|
|
256 | (1) |
|
|
256 | (7) |
|
6.1 Vitamin C deficiency: Etiologies of deficiency, therapy |
|
|
256 | (1) |
|
6.2 Vitamin C excess: Adverse effects |
|
|
256 | (1) |
|
|
257 | (6) |
|
18 Vitamin D in human health |
|
|
|
|
|
|
|
263 | (1) |
|
2 Definition of vitamin D deficiency |
|
|
263 | (1) |
|
3 Causes of vitamin D deficiency |
|
|
264 | (2) |
|
3.1 Exposure to sunlight and cutaneous factors |
|
|
264 | (1) |
|
|
265 | (1) |
|
3.3 Bioavailability of vitamin D after oral ingestion or cutaneous synthesis |
|
|
265 | (1) |
|
4 Vitamin D deficiency and disorders |
|
|
266 | (10) |
|
4.1 Musculoskeletal consequences of vitamin D deficiency |
|
|
266 | (2) |
|
4.2 Nonmusculoskeletal consequences of vitamin D deficiency |
|
|
268 | (7) |
|
|
275 | (1) |
|
|
276 | (7) |
|
|
276 | (1) |
|
|
276 | (7) |
|
19 Vitamin E: Tocopherols and tocotrienol and their role in health and disease |
|
|
|
|
|
|
|
283 | (1) |
|
2 Vitamin E as dietary supplements |
|
|
283 | (1) |
|
3 Is RDA for α-tocopherol set at an appropriate level? |
|
|
284 | (1) |
|
|
285 | (1) |
|
5 Tocopherol and tocotrienol status/intake in obesity and metabolic syndrome |
|
|
285 | (1) |
|
5.1 Obesity and metabolic syndrome |
|
|
286 | (1) |
|
6 A-Tocopherol supplementation in obese individuals |
|
|
286 | (1) |
|
7 Tocotrienol status/intake in obesity |
|
|
286 | (1) |
|
8 Vitamin E in diseases and health |
|
|
287 | (3) |
|
|
287 | (1) |
|
|
287 | (3) |
|
|
290 | (9) |
|
|
290 | (5) |
|
Recommended daily dietary allowances |
|
|
295 | (4) |
Index |
|
299 | |